Patents Issued in June 22, 2017
-
Publication number: 20170174747Abstract: The present invention is directed to systems, apparatus and methods for creating derivatives of at least one form of HDL without substantially affecting LDL. These derivatives of HDL are particles with reduced lipid content, particularly reduced cholesterol content. These particles have the capacity to bind cholesterol and are administered to a patient to enhance cellular cholesterol efflux and reduce cholesterol levels in cells, tissues, organs, and blood vessels. The present method is useful for treating atherogenic vascular disease and may be combined with other therapies such as statins, inhibitors of cholesterol absorption, niacin, anti-inflammatories, exercise and dietary restriction.Type: ApplicationFiled: March 9, 2017Publication date: June 22, 2017Inventors: MARC BELLOTTI, H. BRYAN BREWER, HASSIBULLAH AKEEFE, ADAM PAUL CONNER, TIMOTHY JON PERLMAN
-
Publication number: 20170174748Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.Type: ApplicationFiled: March 19, 2015Publication date: June 22, 2017Inventors: Tracy S. MITCHELL, Michael L. GOSSELIN, Dasa LIPOVSEK, Rex PARKER, Ray CAMPHAUSEN, Jonathan DAVIS, David FABRIZIO
-
Publication number: 20170174749Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumorigenic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties.Type: ApplicationFiled: December 30, 2016Publication date: June 22, 2017Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: ALEKSANDER S. POPEL, ELENA V. ROSCA, JACOB E. KOSKIMAKI, CORBAN G. RIVERA, NIRANJAN B. PANDEY, AMIR P. TAMIZ
-
Publication number: 20170174750Abstract: In one aspect, the invention relates to peptides comprising the Bcr-Abl coiled-coil oligomerization domain and an alpha helix stabilizing moiety, mutant forms thereof, truncated forms thereof, derivatives thereof, and related peptides, which are useful as inhibitors of the Bcr-Abl chimeric protein; pharmaceutical compositions comprising the compounds; and methods of treating hyperproliferative disorders associated with Bcr-Abl using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: March 25, 2015Publication date: June 22, 2017Inventors: Carol LIM, Benjamin J. BRUNO, Geoffrey D. MILLER, Andrew S. DIXON
-
Publication number: 20170174751Abstract: The present invention provides structural determinants important for binding to the stem domain of the HA protein of influenza virus, and methods of use thereof for production of high affinity neutralizing influenza virus antibodies based upon these determinants. The present invention further provides tools for determining the efficacy of an influenza virus vaccine. The present invention further provides a molecular signature useful for determining the efficacy of an influenza virus vaccine in a subject, or for predicting prior immunologic exposure or antigen responsiveness to vaccine or influenza virus infection.Type: ApplicationFiled: March 19, 2015Publication date: June 22, 2017Inventors: Wayne Marasco, Yuval Avnir
-
Publication number: 20170174752Abstract: The invention provides a pharmaceutical composition comprising as an active ingredient a combination of three isolated monoclonal antibodies or any antigen-binding fragment thereof which bind ricin toxin and neutralize its toxic effects, and a pharmaceutically acceptable carrier, excipient or diluent. The invention also provides a method of prophylaxis, treatment or amelioration of ricin toxin poisoning including administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition.Type: ApplicationFiled: January 4, 2017Publication date: June 22, 2017Inventors: Ohad MAZOR, Ronit ROSENFELD, Arie ORDENTLICH, Tal NOY-PORAT
-
Publication number: 20170174753Abstract: Breast cancer cells lacking ER protein expression, PgR protein expression and/or showing absence of HER2 protein over-expression (i.e., triple-negative breast cancer cells, basal-like) can be efficiently targeted with an anti-KAAG1 antibody and killed upon delivery of a therapeutic moiety. Antibodies and antigen binding fragments that specifically binds to KAAG1 may thus be used for the, detection and therapeutic treatment of breast cancer cells that are negative for at least one of these markers. The use of antibody conjugates in the treatment of triple-negative breast cancer and/or basal-like breast cancer is disclosed herein.Type: ApplicationFiled: January 9, 2013Publication date: June 22, 2017Applicant: Alethia Biotherapeutics Inc.Inventors: Gilles Bernard TREMBLAY, Anna N. MORAITIS, Mario FILION
-
Publication number: 20170174754Abstract: The present invention is directed to antibodies and fragments thereof having binding specificity for CGRP. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-CGRP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-CGRP antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-CGRP antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with CGRP.Type: ApplicationFiled: September 6, 2016Publication date: June 22, 2017Inventors: Brian Robert Kovacevich, Leon F. Garcia-Martinez, Katie Olson Anderson, Benjamin H. Dutzar, Jens J. Billgren, John A. Latham, Danielle M. Mitchell, Patricia Dianne McNeill, Nicole M. Janson, Maria-Cristina Loomis
-
Publication number: 20170174755Abstract: The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.Type: ApplicationFiled: January 3, 2017Publication date: June 22, 2017Inventors: Irene GRISWOLD-PRENNER, Nancy E. STAGLIANO, Vu Cao DANG
-
Publication number: 20170174756Abstract: Stabilized antibodies directed to Angiopoeitin-2 and uses of such antibodies are described. Nucleic acid and amino acid sequences, hybridomas or other cell lines for expressing such antibodies are also provided.Type: ApplicationFiled: October 27, 2016Publication date: June 22, 2017Inventors: VAHE BEDIAN, William DALL'ACQUA, Herren WU, Michael BOWEN, Jeffrey BROWN, Ralph MINTER, Andrew BUCHANAN
-
Publication number: 20170174757Abstract: The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. increased serum half-life in vivo.Type: ApplicationFiled: February 27, 2017Publication date: June 22, 2017Inventors: Gregory Lazar, Bassil I. Dahiyat, Matthew J. Bernett
-
Publication number: 20170174758Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.Type: ApplicationFiled: July 26, 2016Publication date: June 22, 2017Inventor: Mir Imran
-
Publication number: 20170174759Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.Type: ApplicationFiled: December 16, 2016Publication date: June 22, 2017Applicants: Singapore Health Services PTE LTD., National University of SingaporeInventors: Stuart Alexander Cook, Sebastian Schaefer
-
Publication number: 20170174760Abstract: Described herein are methods for treating antibody mediated rejection of transplanted organs using inhibitors of IL-6. In one embodiment, the IL-6 inhibitor is Tocilizumab and is administered simultaneously or sequentially with intravenous immunoglobulin (IVIG).Type: ApplicationFiled: March 2, 2017Publication date: June 22, 2017Applicant: Cedars-Sinai Medical CenterInventors: Stanley C. Jordan, Ashley Vo, Jua Choi
-
Publication number: 20170174761Abstract: The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof. The present disclosure is further directed to methods comprising detection of progastrin, including methods of diagnosing colorectal cancer and methods of monitoring efficacy of anti-cancer therapy in subjects suffering from colorectal cancer.Type: ApplicationFiled: March 6, 2017Publication date: June 22, 2017Inventors: Julie PANNEQUIN, Laure BOU DIER, Dominique JOUBERT, Frédéric HOLLANDE
-
Publication number: 20170174762Abstract: The invention provides novel biparatopic LRP5/LRP6 cross-reactive binding polypeptides, and more specifically novel biparatopic LRP5/LRP6 cross-reactive immunoglobulin single variable domain constructs which can inhibit Wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.Type: ApplicationFiled: December 2, 2016Publication date: June 22, 2017Inventors: Vittoria ZINZALLA, Klaus-Peter KUENKELE, Marie-Ange BUYSE, Karen CROMIE, Stephanie STAELENS, Beatrijs STRUBBE
-
Publication number: 20170174763Abstract: Disclosed are NgR proteins and biologically active Nogo (ligand) protein fragments. Also disclosed are compositions and methods for modulating the expression or activity of the Nogo and NgR protein. Also disclosed are peptides which block Nogo-mediated inhibition of axonal extension. The compositions and methods of the invention are useful in the treatment of cranial or cerebral trauma, spinal cord injury, stroke or a demyelinating disease.Type: ApplicationFiled: July 13, 2015Publication date: June 22, 2017Inventor: Stephen M. STRITTMATTER
-
Publication number: 20170174764Abstract: The present invention provides isolated peptides derived from TCR CDR3 segments, antibodies which recognize them, pharmaceutical compositions comprising them and methods of their use for modulating self-immunity.Type: ApplicationFiled: March 26, 2015Publication date: June 22, 2017Inventors: Irun R. COHEN, Nir FRIEDMAN, Asaf MADI, Eric SHIFRUT, Shlomit REICH-ZELIGER, Asaf PORAN
-
Publication number: 20170174765Abstract: The present invention provides a bispecific antibody. The bispecific antibody provided by the present invention comprises a single-chain unit and a monovalent unit, wherein the single-chain unit has a specific binding capability against a surface antigen CD3 of an immune cell; the monovalent unit has a specific binding capability against a surface antigen HER2 of a tumor cell; the single-chain unit comprises a single-chain variable fragment ScFv fused with an Fc fragment; and the monovalent unit comprises a light chain and heavy chain pair. The present invention also provides a preparation method of the bispecific antibody and pharmaceutical use of these antibodies.Type: ApplicationFiled: March 3, 2017Publication date: June 22, 2017Inventors: Pengfei Zhou, Jing Zhang, Lingli Hu, Rui Wang, Xiang Zhou, Kesu Fan
-
Publication number: 20170174766Abstract: Herein described as liquid formulations of antibodies and biologically active fragments thereof that specifically bind to human ICOS polypeptide, exhibit increased in vivo ADCC activity and undergo reversible self-association in solution.Type: ApplicationFiled: December 12, 2016Publication date: June 22, 2017Inventors: Hasige Sathish, Ambarish Shah, Gianluca Carlesso, Tracy Delaney
-
Publication number: 20170174767Abstract: The present invention relates to an ICOS binding protein or antigen binding portion thereof that is an agonist to human ICOS and does not induce complement, ADCC, or CDC when placed in contact with a T cell in vivo and methods of treating cancer, infectious disease and/or sepsis with said ICOS binding protein or antigen binding portion thereof. Further the ICOS binding proteins or antigen binding portions thereof of the present invention are capable of activating a T cell when placed in contact with said T cell; stimulating T cell proliferation when placed in contact with said T cell and/or inducing cytokine production when placed in contact with said T cell. The present invention relates to ICOS binding proteins or antigen binding portions thereof comprising one or more of: SEQ ID NO:1; SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and/or SEQ ID NO:6.Type: ApplicationFiled: December 21, 2016Publication date: June 22, 2017Inventors: Yao-Bin LIU, Patrick Mayes, Radha Shah Parmar
-
Publication number: 20170174768Abstract: The present invention relates to antibodies targeted to BDCA2 that deplete plasmacytoid dendritic cells (pDC) and methods of using the antibodies to treat disorders associated with pDC.Type: ApplicationFiled: February 24, 2017Publication date: June 22, 2017Inventor: Lishan Su
-
Publication number: 20170174769Abstract: The present invention provides agonists of FGF21 signaling. In particular, the present invention provides FGF21 receptor (FGF21R) agonists that are capable of simultaneously binding ?Klotho (KLB) and/or FGFR1c to mimic the signaling activity of FGF21. The present invention also provides anti-FGF21 and anti-KLB/FGFR1c antibodies and antigen-binding fragments thereof. Also provided are methods of treating various metabolic disorders by administering the FGF21R agonists and/or anti-FGF21 antibodies to a subject in need thereof.Type: ApplicationFiled: March 25, 2015Publication date: June 22, 2017Inventors: George D. YANCOPPULOS, Andrew J. MURPHY, Jesper GROMADA, David R. BUCKLER, Kihwa KANG
-
Publication number: 20170174770Abstract: The invention relates to polynucleotides, particularly chimeric polynucleotides useful for optimal production of functional immunoglobulins with human idiotypes in rodents. The invention further relates to rodents comprising such polynucleotides.Type: ApplicationFiled: October 24, 2016Publication date: June 22, 2017Inventors: Marianne BRUGGEMANN, Roland BUELOW, Michael J. OSBORN, Biao MA
-
Publication number: 20170174771Abstract: The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.Type: ApplicationFiled: March 3, 2017Publication date: June 22, 2017Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Richard A. Morgan, Steven A. Rosenberg
-
Publication number: 20170174772Abstract: The present invention relates to a therapeutic agent for nail and scalp psoriasis comprising an IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as monoclonal antibodies that bind IL-17RA, and method of using the same.Type: ApplicationFiled: March 19, 2015Publication date: June 22, 2017Applicant: Kirin-Amgen, Inc.Inventors: Ajay Nirula, Hidemi Nakagawa, Kenji Ohtaki, Hiroki Matsudo, Paul Klekotka, Gregory Kricorian
-
Publication number: 20170174773Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a selective 4-1 BB agonist, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.Type: ApplicationFiled: February 3, 2015Publication date: June 22, 2017Inventors: Craig Bennett Davis, Maria Theresa Koehler, Li Yan
-
Publication number: 20170174774Abstract: This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.Type: ApplicationFiled: December 19, 2016Publication date: June 22, 2017Inventors: Vladimir CORIC, Tibor Keler, Thomas Davis
-
Publication number: 20170174775Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: ApplicationFiled: December 21, 2016Publication date: June 22, 2017Inventors: Laurent JESPERS, Malgorzata PUPECKA-SWIDER, Carolyn Enever, Ian Tomlinson
-
Publication number: 20170174776Abstract: Herein is reported a fusion polypeptide comprising i) at least one binding site, e.g. which comprises an antibody heavy chain variable domain and an antibody light chain variable domain, and which binds to an internalizing cell surface receptor, and ii) at least one pharmaceutically active compound, whereby the EC50-value of the binding pair that binds to an internalizing cell surface receptor determined at pH 5.5 is higher than the EC50-value of the same binding pair determined at pH 7.4 and its use for delivering a pharmaceutically active compound across the blood-brain-barrier.Type: ApplicationFiled: December 1, 2015Publication date: June 22, 2017Applicant: Roche Glycart AGInventors: Bernd Bohrmann, Per-Ola Freskgard, Adrian Hugenmatter, Erhard Kopetzki, Ekkehard Moessner, Jens Niewoehner, Hadassah Sumum Sade, Pablo Umaña
-
Publication number: 20170174777Abstract: The invention provides blood-brain barrier shuttles comprising monoclonal antibody 5C1 and related antibodies linked to a monovalent binding entity for a blood-brain barrier receptor. The 5C1 antibody binds to an epitope within residues 118-126 of alpha-synuclein. The antibodies are useful, for example, for treating and/or diagnosing synucleinopathies including Lewy body diseases, such as Parkinson's disease, diffuse Lewy body disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Alzheimer's and Parkinson's disease comorbidity, and pure autonomic failure, as well as multiple system atrophy (MSA).Type: ApplicationFiled: April 8, 2015Publication date: June 22, 2017Inventors: Robin Barbour, Kate Dora Games-Thiel, Tarlochan S. Nijar, Wagner Zago, Olaf Mundigl, Jens Niewoehner, Georg Tiefenthaler
-
Publication number: 20170174778Abstract: A pH-dependent antibody that binds an antigen with high affinity at a first pH and rapidly dissociates at a second pH, wherein the antigen is a transferrin receptor (TfR), wherein the association at the second pH/the first pH is less than 20%, and wherein the pH-dependent antibody comprises at least two consecutive histidine residues at a single complementarity determining region (CDR) is disclosed.Type: ApplicationFiled: December 15, 2016Publication date: June 22, 2017Inventors: Eric V. Shusta, Benjamin J. Tillotson
-
Publication number: 20170174779Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., a B-cell cancer such as Hodgkin's lymphoma or acute lymphoblastic leukemia). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to programmed death 1 (PD-1) receptor in combination with a therapeutically effective amount of a bispecific antibody that specifically binds to CD20 and CD3.Type: ApplicationFiled: December 21, 2016Publication date: June 22, 2017Inventors: Bindu VARGHESE, Gavin THURSTON, Israel LOWY, Carrie BROWNSTEIN
-
Publication number: 20170174780Abstract: The present invention relates to combination therapies with anti-CD38 antibodies.Type: ApplicationFiled: February 28, 2017Publication date: June 22, 2017Inventor: Parul Doshi
-
Publication number: 20170174781Abstract: The present invention provides methods for treating, reducing the severity, or inhibiting the growth of acute lymphoblastic leukemia. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a bispecific antibody that specifically binds to CD20 and CD3.Type: ApplicationFiled: December 21, 2016Publication date: June 22, 2017Inventor: Carrie Brownstein
-
Publication number: 20170174782Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.Type: ApplicationFiled: October 18, 2016Publication date: June 22, 2017Applicant: Genentech, Inc.Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
-
Publication number: 20170174783Abstract: Provided herein are monovalent antibody constructs. In specific embodiments is a monovalent antibody construct comprising: an antigen-binding polypeptide construct which monovalently binds an antigen; and a dimeric Fc polypeptide construct comprising a CH3 domain, said construct comprising two monomeric Fc polypeptides, wherein one said monomeric Fc polypeptide is fused to at least one polypeptide from the antigen-binding polypeptide construct. These therapeutically novel molecules encompass monovalent constructs that display an increase in binding density and Bmax (maximum binding at a target to antibody ratio of 1:1) to a target cell displaying said antigen as compared to a corresponding monospecific bivalent antibody construct with two antigen binding regions. Provided herein are methods for creation of monovalent antibody constructs that shows superior effector efficacy as compared to the corresponding bivalent antibody construct at equimolar concentrations.Type: ApplicationFiled: October 20, 2016Publication date: June 22, 2017Inventors: Gordon Yiu Kon NG, Surjit Bhimarao DIXIT, Thomas SPRETER VON KREUDENSTEIN
-
Publication number: 20170174784Abstract: The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: February 17, 2017Publication date: June 22, 2017Applicant: Roche Glycart AGInventors: Birgit Bossenmaier, Nikolaos Dimoudis, Thomas Friess, Guy Georges, Irene Kolm, Hans-Willi Krell, Valeria Lifke, Ekkehard Moessner
-
Publication number: 20170174785Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.Type: ApplicationFiled: March 6, 2017Publication date: June 22, 2017Applicant: Genentech, Inc.Inventors: Reed J Harris, Paul A. Motchnick
-
Publication number: 20170174786Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: September 30, 2016Publication date: June 22, 2017Applicant: Hoffmann-La Roche Inc.Inventors: Marina Bacac, Christian Klein, Wolfgang Schaefer, Stefan Klostermann, Sabine Imhof-Jung, Michael Molhoj, Joerg Thomas Regula, Pablo Umana, Sylvia Herter, Christiane Neumann
-
Publication number: 20170174787Abstract: Modulators of Wnt activity, e.g., Wnt inhibitors, that act on TIKI proteins and inhibit TIKI-mediated cleavage of Wnt proteins, as well as methods of identifying such modulators and methods of use thereof.Type: ApplicationFiled: November 21, 2016Publication date: June 22, 2017Inventors: Xi He, Xinjun Zhang, Bryan MacDonald
-
Publication number: 20170174788Abstract: Provided herein are methods and pharmaceutical compositions for the treatment of inflammatory disorders comprising filgotinib and a matrix metalloproteinase-9 (MMP9) binding protein.Type: ApplicationFiled: December 15, 2016Publication date: June 22, 2017Inventors: Sunhwa Kim, Victoria Smith
-
Publication number: 20170174789Abstract: The present invention provides antibodies that bind to Tie2 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Tie2 and block the interaction between Tie2 and one or more Tie2 ligands such as angiopoietin 1 (Ang1), angiopoietin 2 (Ang2), angiopoietin 3 (Ang3) and/or angiopoietin 4 (Ang4). The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Tie2 biological activities including angiogenesis. In certain embodiments, pairs of activating Tie-2 antibodies showed an additive effect on the treatment of influenza infection when combined with anti-influenza HA. In other embodiments, prophylactic administration pairs of activating Tie2 antibodies delayed death and improved survival in a lethal model of E. coli intoxication (sepsis) over isotype/untreated controls.Type: ApplicationFiled: February 28, 2017Publication date: June 22, 2017Inventor: Gavin Thurston
-
Publication number: 20170174790Abstract: The present disclosure provides antibodies and antigen-binding fragments capable of penetrating cells via an ENT transporter, such as humanized antibodies. The disclosure also provides conjugates comprising the antibodies or antigen-binding fragments and a heterologous agent. The disclosure further provides methods for making and using the antibodies, antigen-binding fragments and conjugates, including humanized antibodies.Type: ApplicationFiled: January 13, 2015Publication date: June 22, 2017Inventors: Dustin D. ARMSTRONG, Jeffrey C. WAY
-
Publication number: 20170174791Abstract: An antibody is provided. The antibody comprises an Fc region and a Fab region, wherein: (i) the Fc region comprises two non-identical heavy chains, wherein at least one of the two non-identical heavy chains comprises an amino acid modification so as to form complementation between the two non-identical heavy chains thereby increasing the probability of forming heterodimers of the non-identical heavy chains and decreasing the probability of forming homodimers of identical heavy chains; and (ii) the Fab region comprises a first covalent link between a first heavy chain and a first light chain of the Fab region and a second covalent link between a second heavy chain and a second light chain of said Fab region, wherein a position of the first covalent link relative to the first heavy chain is different to a position of the second covalent link relative to the second heavy chain. Methods of generating same and uses thereof are also provided.Type: ApplicationFiled: March 2, 2017Publication date: June 22, 2017Applicant: Ramot at Tel-Aviv University Ltd.Inventors: Itai BENHAR, Lilach VAKS
-
Publication number: 20170174792Abstract: The invention relates to a carbohydrate composition characterized in that it has a dextrose equivalence of from 20 to 25 and further characterized in that it has a fibre content of from 10 to 90% by weight of the composition on dry basis. The invention further relates to a process for making a carbohydrate composition. Further the invention relates to a food, feed, pet food, pharmaceutical, cosmetic and industrial products comprising the carbohydrate composition of the present invention and other ingredients and to the use of the carbohydrate composition of the present invention.Type: ApplicationFiled: March 26, 2015Publication date: June 22, 2017Inventor: Ronny Leontina Marcel VERCAUTEREN
-
Publication number: 20170174793Abstract: The present invention relates to a compound which is a di- and/or a tristyrylphenol monoglycidyl ether adduct of the compound of Formula I: where m is from 1 to 60. The compound of the present invention is useful as an open time additive in coatings formulations.Type: ApplicationFiled: December 12, 2016Publication date: June 22, 2017Inventors: David J. Brennan, Gregoire Cardoen, Jonathan DeRocher, Robert E. Hefner, JR., Antony K. Van Dyk, Tianlan Zhang
-
Publication number: 20170174794Abstract: A polymer comprises randomly distributed units UA, UB, UC and UD and at least one unit bearing a subunit F according to the respective molar percentages m, n, o, p and f F pendant along the chain of the polymer and bearing an associative group comprising at least one nitrogen atom, R1 and R2, which are identical or different, denoting a hydrogen atom, a methyl radical or a phenyl radical which is unsubstituted or substituted in the ortho, meta or para position by a methyl radical, m?50, n?0, o?0, f>0, 0<o+p?25, m, n, o, p and f ranging from 0 to 100, the respective molar percentages of m, n, o, p and f calculated based on the sum of m+n+p+f, which is equal to 100.Type: ApplicationFiled: July 9, 2015Publication date: June 22, 2017Inventors: Etienne FLEURY, Julien THUILLIEZ, Jean-Michel FAVROT
-
Publication number: 20170174795Abstract: The invention relates to a method to reduce or prevent agglomeration of particles of optionally halogenated rubbers in aqueous media by LCST compounds, their purification as well as ultrapure optionally halogenated rubbers. The invention further relates to (halogenated) copolymer products comprising the same or derived therefrom.Type: ApplicationFiled: July 21, 2015Publication date: June 22, 2017Applicant: ARLANXEO Singapore Pte. Ltd.Inventors: Conrad SIEGERS, David THOMPSON
-
Publication number: 20170174796Abstract: The present invention generally relates to alcohol-terminated polyisobutylene (PIB) compounds, and to a process for making such compounds. In one embodiment, the present invention relates to primary alcohol-terminated polyisobutylene compounds, and to a process for making such compounds. In still another embodiment, the present invention relates to polyisobutylene compounds that can be used to synthesize polyurethanes, to polyurethane compounds made via the use of such polyisobutylene compounds, and to processes for making such compounds. In yet another embodiment, the present invention relates to primary alcohol-terminated polyisobutylene compounds having two or more primary alcohol termini and to a process for making such compounds. In yet another embodiment, the present invention relates to primary terminated polyisobutylene compounds having two or more primary termini selected from amine groups or methacrylate groups.Type: ApplicationFiled: March 2, 2017Publication date: June 22, 2017Inventors: Joseph KENNEDY, Yongmoon KWON, Subramanyam UMMADISETTY